PharmaCyte Biotech PMCB Insider Ownership

NASDAQ PMCB

$0.35 +0.01 (+2.94%)

At close: Oct 22, 2026 · 4:00 PM EDT

Insider Holdings by Owner

608.75K Shares

Insider Ownership Statistics

as of 30 Sep, 2026

Insider Ownership

5.67%

■0% pp QoQ

Shares Held by Insiders

608.75K

filed for Sep 2026

■0.00% QoQ

Shares Outstanding

10.74Mn

10,735,649 shares

Direct Holdings

608.75K

Indirect: 0

Net Shares Traded (QoQ)

no net change in Sep 2026

Insiders Holding Shares

with Form 4 holdings on file

Shares Owned by Insiders

Shares held % of outstanding

Latest —

Average ownership —

Peak ownership —

Shares Purchased/Sold by Insiders

Bought Sold

Latest quarter —

Net over range —

Buying quarters —

Insider Ownership Summary

Updated Oct 10, 2026

Over the past year, PMCB insiders bought $128,708 of stock (160K shares) on the open market and sold none.

By number of insiders, PharmaCyte Biotech saw 2 insiders buy on the open market over the past 12 months and none sell.
Among PMCB's insiders, Joshua Silverman (CEO and President) was the top open-market buyer in the past 12 months, with $80,476 of stock purchased (100K shares) and the latest purchase on January 7, 2026.
Away from the open market, PMCB insiders received 575K shares in stock awards and gave up 258.75K shares to cover taxes or exercise prices over the last 12 months.
Business Quant data shows PharmaCyte Biotech insiders holding 608.75K shares in total in their latest Form 4 filings, unchanged from 608.75K shares at the end of Q2 2026.
By type of ownership, PMCB insiders hold all of their 608.75K shares directly.
Per Business Quant, 2 insiders of PMCB hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
PMCB's largest insider holders by reported holdings are Joshua Silverman (CEO and President, 416.25K shares) and Jonathan Schechter (Director, 192.5K shares).
Joshua Silverman holds 68.38% of the combined insider position in PharmaCyte Biotech.
Institutions accounted for 7.10% of PMCB's outstanding shares in Q2 2026, insiders about 5.67% per their latest Form 4 filings, and other investors, including the public, about 87.23%.
A total of 7 Form 4 filings with transactions in PharmaCyte Biotech stock were made over the past 12 months, by 5 insiders.
This summary of PharmaCyte Biotech insider activity covers Form 4 filings through April 2, 2026.

Form 4 Holdings

Insiders Holding PMCB

Insiders 2

Shares held 608.75K

Of outstanding 5.67%

#	Insider	Position	Direct	Indirect	Total	Share of Insiders	Last Filed
1	Joshua Silverman	Ceo And President	416,250	0	416,250	68.4%	07 Jan, 2026
2	Jonathan Schechter	Director	192,500	0	192,500	31.6%	07 Jan, 2026

Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.

Form 4 Filings

20 Insider Transactions

Source SEC Form 4

Latest quarter Sep 2026

Date	Insider	Position	Transaction	Shares	Price	Value	Shares Held After	Ownership
31 Mar, 2026	Robert Weinstein	Director	Acquired A	119,170	$0.00	$0	119,170	Direct
31 Mar, 2026	Wayne Remell Walker	Director	Acquired A	119,170	$0.00	$0	119,170	Direct
31 Mar, 2026	Jonathan Schechter	Director	Acquired A	119,170	$0.00	$0	119,170	Direct
31 Mar, 2026	Michael M Abecassis	Director	Acquired A	119,170	$0.00	$0	119,170	Direct
05 Jan, 2026	Jonathan Schechter	Director	Acquired P	20,000	$0.78	$15.55K	152,500	Direct
05 Jan, 2026	Joshua Silverman	Ceo And President	Acquired P	30,000	$0.78	$23.49K	346,250	Direct
06 Jan, 2026	Joshua Silverman	Ceo And President	Acquired P	30,000	$0.79	$23.67K	376,250	Direct
06 Jan, 2026	Jonathan Schechter	Director	Acquired P	20,000	$0.79	$15.81K	172,500	Direct
07 Jan, 2026	Jonathan Schechter	Director	Acquired P	20,000	$0.84	$16.87K	192,500	Direct
07 Jan, 2026	Joshua Silverman	Ceo And President	Acquired P	40,000	$0.83	$33.32K	416,250	Direct
12 Dec, 2025	Joshua Silverman	Ceo And President	Acquired A	575,000	$0.00	$0	575,000	Direct
12 Dec, 2025	Joshua Silverman	Ceo And President	Disposed F	258,750	$1.02	$263.93K	316,250	Direct
20 Nov, 2023	Jonathan Schechter	Director	Acquired A	61,248	$0.00	$0	61,248	Direct
20 Nov, 2023	Wayne Remell Walker	Director	Acquired A	61,248	$0.00	$0	61,248	Direct
20 Nov, 2023	Joshua Silverman	Interim Ceo, Interim President	Acquired A	170,000	$0.00	$0	170,000	Direct
20 Nov, 2023	Carlos Trujillo	Chief Financial Officer	Acquired A	85,000	$0.00	$0	85,000	Direct
20 Nov, 2023	Robert Weinstein	Director	Acquired A	61,248	$0.00	$0	61,248	Direct
20 Nov, 2023	Michael M Abecassis	Director	Acquired A	61,248	$0.00	$0	61,248	Direct
28 Dec, 2022	Daniel Allen	Director	Acquired A	125,000	$0.00	$0	125,000	Direct
28 Dec, 2022	Daniel Stuart Farb	Director	Acquired A	125,000	$0.00	$0	125,000	Direct